Alzheimer's Disease - Pipeline Review, H2 2011

Published by: Global Markets Direct

Published: Sep. 28, 2011 - 168 Pages


Table of Contents

Introduction
Global Markets Direct Report Coverage
Alzheimer's Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Alzheimer's Disease
Alzheimer's Disease Therapeutics under Development by Companies
Alzheimer's Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Alzheimer's Disease Therapeutics - Products under Development by Companies
Alzheimer's Disease Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Alzheimer's Disease Therapeutics Development
Bristol-Myers Squibb Company
Baxter International Inc.
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Biogen Idec Inc.
NsGene A/S
Sanofi-Aventis
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
Merck & Co., Inc.
United Biomedical, Inc.
Dainippon Sumitomo Pharma Co., Ltd.
Euroscreen S.A.
Applied NeuroSolutions, Inc.
ExonHit Therapeutics SA
Avineuro Pharmaceuticals, Inc.
Nanotherapeutics, Inc.
Senexis Limited
Novartis AG
Samyang Corporation
Aphios Corporation
EnVivo Pharmaceuticals
DECODON GmbH
Astellas Pharma Inc.
Chiesi Farmaceutici SpA
BELLUS Health Inc
ReGenX Biosciences, LLC
Neuro-Hitech, Inc.
Nymox Pharmaceutical Corporation
Osta Biotechnologies Inc.
Cortex Pharmaceuticals, Inc.
Critical Outcome Technologies Inc.
PharmAthene, Inc.
ACADIA Pharmaceuticals Inc.
Medivation, Inc.
ProteoTech, Inc.
WhanIn Pharmaceutical Co., Ltd.
Phytopharm Plc
SYGNIS Pharma AG
Prana Biotechnology Limited
Biotie Therapies Corp.
Transition Therapeutics Inc.
Allon Therapeutics Inc.
Bio-Link
D-Pharm Ltd.
StemCells, Inc.
Probiodrug AG
Snowdon Inc.
Varinel, Inc.
Cognosci, Inc.
Reviva Pharmaceuticals Inc.
RaQualia Pharma Inc.
Immune Technologies and Medicine
PharmaNeuroBoost N.V.
Alzheimer's Disease - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Dimebon - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Florbetaben - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bapineuzumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2062430 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vitamin E + Selenium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rifampin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Valproate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AC-1204 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WIN-026 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rivastigmine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARC029 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gammagard Liquid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alzheimer's Disease Therapeutics - Drug Profile Updates
Alzheimer's Disease Therapeutics - Discontinued Products
Alzheimer's Disease - Featured News
Sep 19, 2011: Prana’s PBT2 Directly Restores Neurons Critical To Cognition
Sep 15, 2011: Anavex To Present Data On ANAVEX 2-73 At Japan Neuroscience Society Special Symposium
Sep 14, 2011: Prana Biotechnology Presents Research Data On PBT2 At World Congress On Huntington’s Disease, Melbourne
Sep 01, 2011: StemCells Receives CIRM Planning Grant To Pursue Preclinical Development Of HuCNS-SC Cells For Alzheimer's Disease
Jul 26, 2011: Anavex Presents Data On Neuroprotective Evidence Of ANAVEX 2-73 For Alzheimer’s Disease
Jul 25, 2011: Anavex Presents Data On Potential Dual Utility Of ANAVEX 2-73 In Both Amyloid And Tau Pathology
Jul 25, 2011: Biotie Advances Clinical Program Of SYN120 With Imaging Study At Johns Hopkins Center Of Excellence
Jul 20, 2011: Bristol-Myers Squibb Announces Results From Phase II Study Of BMS-708163 In Patients With Alzheimer’s Disease
Jul 19, 2011: Theratechnologies Presents Results Of Independent Study On Effect Of Tesamorelin On Cognitive Function At Conference In France
Jul 15, 2011: Anavex To Present At Alzheimer’s Association International Conference On Alzheimer’s Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Alzheimer's Disease, H2 2011
Products under Development for Alzheimer's Disease - Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, H2 2011
Baxter International Inc., H2 2011
Johnson & Johnson, H2 2011
Boehringer Ingelheim GmbH, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Abbott Laboratories, H2 2011
Biogen Idec Inc., H2 2011
NsGene A/S, H2 2011
Sanofi-Aventis, H2 2011
AstraZeneca PLC, H2 2011
Eli Lilly and Company, H2 2011
GlaxoSmithKline plc, H2 2011
Daiichi Sankyo Company, Ltd, H2 2011
Merck & Co., Inc., H2 2011
United Biomedical, Inc., H2 2011
Dainippon Sumitomo Pharma Co., Ltd., H2 2011
Euroscreen S.A., H2 2011
Applied NeuroSolutions, Inc., H2 2011
ExonHit Therapeutics SA, H2 2011
Avineuro Pharmaceuticals, Inc., H2 2011
Nanotherapeutics, Inc., H2 2011
Senexis Limited, H2 2011
Novartis AG, H2 2011
Samyang Corporation, H2 2011
Aphios Corporation, H2 2011
EnVivo Pharmaceuticals, H2 2011
DECODON GmbH, H2 2011
Astellas Pharma Inc., H2 2011
Chiesi Farmaceutici SpA, H2 2011
Daewoong Pharmaceutical Co., Ltd., H2 2011
Eisai Co., Ltd., H2 2011
Elan Corporation, plc, H2 2011
H Lundbeck A/S, H2 2011
Kowa Company, Ltd., H2 2011
Octapharma AG, H2 2011
Orion Corporation, H2 2011
Pfizer Inc., H2 2011
Sigma-Tau S.p.A., H2 2011
Sunesis Pharmaceuticals, Inc., H2 2011
Toyama Chemical Co. Ltd, H2 2011
Hadasit Medical Research Services & Development Ltd, H2 2011
ENKAM Pharmaceuticals A/S, H2 2011
Astex Therapeutics Limited, H2 2011
Bayer AG, H2 2011
Merck KGaA, H2 2011
Addex Pharmaceuticals, H2 2011
Evotec Aktiengesellschaft, H2 2011
Anavex Life Sciences Corp., H2 2011
Amicus Therapeutics, Inc., H2 2011
Genfit, H2 2011
Ligand Pharmaceuticals Incorporated, H2 2011
Lixte Biotechnology Holdings, Inc., H2 2011
BELLUS Health Inc, H2 2011
ReGenX Biosciences, LLC, H2 2011
Neuro-Hitech, Inc., H2 2011
Nymox Pharmaceutical Corporation, H2 2011
Osta Biotechnologies Inc., H2 2011
Cortex Pharmaceuticals, Inc., H2 2011
Critical Outcome Technologies Inc., H2 2011
PharmAthene, Inc., H2 2011
ACADIA Pharmaceuticals Inc., H2 2011
Medivation, Inc., H2 2011
ProteoTech, Inc., H2 2011
WhanIn Pharmaceutical Co., Ltd., H2 2011
Phytopharm Plc, H2 2011
SYGNIS Pharma AG, H2 2011
Prana Biotechnology Limited, H2 2011
Biotie Therapies Corp., H2 2011
Transition Therapeutics Inc., H2 2011
Allon Therapeutics Inc., H2 2011
Neurim Pharmaceuticals (1991) Ltd., H2 2011
Samaritan Pharmaceuticals, Inc., H2 2011
Theravance, Inc., H2 2011
Suven Life Sciences Ltd., H2 2011
Galapagos NV, H2 2011
MediPost Co., Ltd., H2 2011
Proximagen Neuroscience plc., H2 2011
Newron Pharmaceuticals S.p.A., H2 2011
DiaMedica Inc., H2 2011
e-Therapeutics plc, H2 2011
Mithridion, Inc., H2 2011
Teikoku Pharma USA, Inc., H2 2011
Digna Biotech, S.L., H2 2011
Oryzon, H2 2011
TauRx Therapeutics Ltd, H2 2011
Ceregene, Inc., H2 2011
CoMentis, Inc., H2 2011
AC Immune SA, H2 2011
Debiopharm Group, H2 2011
Humanetics Corporation, H2 2011
AFFiRiS AG, H2 2011
Noscira, S.A., H2 2011
Accera, Inc., H2 2011
Sonexa Therapeutics, Inc., H2 2011
Bio-Link, H2 2011
D-Pharm Ltd., H2 2011
StemCells, Inc., H2 2011
Probiodrug AG, H2 2011
Snowdon Inc., H2 2011
Wellstat Therapeutics Corporation, H2 2011
BIOALVO S.A., H2 2011
Hawthorn Pharmaceuticals, Inc., H2 2011
Opsona Therapeutics Ltd., H2 2011
BioArctic Neuroscience AB, H2 2011
Affichem, H2 2011
QR Pharma, Inc., H2 2011
NeuroNascent, Inc., H2 2011
Siena Biotech S.p.A., H2 2011
SeneXta Therapeutics SA, H2 2011
KineMed, Inc., H2 2011
Intellect Neurosciences, Inc., H2 2011
Xencor, Inc., H2 2011
Adeona Pharmaceuticals, Inc., H2 2011
Intra-Cellular Therapies, Inc., H2 2011
Targacept, Inc., H2 2011
RemeGenix, Inc., H2 2011
AB Science, H2 2011
Tautatis Incorporated, H2 2011
Krenitsky Pharmaceuticals Inc., H2 2011
Lipopharma, H2 2011
Link Medicine Corporation, H2 2011
PALUMED S.A., H2 2011
M's Science Corporation, H2 2011
NasVax Ltd., H2 2011
Stelic Institute & Co., H2 2011
EUSA Pharma, Inc., H2 2011
Heptares Therapeutics Ltd., H2 2011
Signum Biosciences, Inc., H2 2011
ArmaGen Technologies, Inc., H2 2011
B&C Biopharm, H2 2011
BioChromix Pharma AB, H2 2011
Archer Pharmaceuticals, Inc., H2 2011
Varinel, Inc., H2 2011
Cognosci, Inc., H2 2011
Reviva Pharmaceuticals Inc., H2 2011
RaQualia Pharma Inc., H2 2011
Immune Technologies and Medicine, H2 2011
PharmaNeuroBoost N.V., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Alzheimer's Disease Therapeutics - Drug Profile Updates
Discontinued Products
List of Figures
Number of Products under Development for Alzheimer's Disease, H2 2011
Products under Development for Alzheimer's Disease - Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Abstract

Alzheimer's Disease - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Alzheimer's Disease - Pipeline Review, H2 2011', provides an overview of the Alzheimer's Disease therapeutic pipeline. This report provides information on the therapeutic development for Alzheimer's Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alzheimer's Disease. 'Alzheimer's Disease - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Alzheimer's Disease.
  • A review of the Alzheimer's Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Alzheimer's Disease pipeline on the basis of route of administration and molecule type.
  • Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Alzheimer's Disease.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Alzheimer's Disease pipeline depth and focus of Alzheimer's Disease therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.


Get full details about this report >>
 
Learn more about this product


Price and delivery options
Search Inside Report

US: 800.298.5699

Int'l: +1.240.747.3093

 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 400,000 market research reports, company profiles and country profiles from over 720 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.